Arctic Bioscience AS
OSE:ABS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Arctic Bioscience AS
Total Assets
Arctic Bioscience AS
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Arctic Bioscience AS
OSE:ABS
|
Total Assets
kr279.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Total Assets
kr146.5m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Total Assets
kr361.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
14%
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Total Assets
$100m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Total Assets
kr12.7m
|
CAGR 3-Years
-71%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
-13%
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Total Assets
kr708.6m
|
CAGR 3-Years
34%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
Arctic Bioscience AS
Glance View
Arctic Bioscience AS engages in the development, manufacturing, and marketing of marine ingredients extracted from herring roe. The company is headquartered in Orsta, More Og Romsdal. The company went IPO on 2021-02-24. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The firm is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The firm's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
See Also
What is Arctic Bioscience AS's Total Assets?
Total Assets
279.7m
NOK
Based on the financial report for Dec 31, 2024, Arctic Bioscience AS's Total Assets amounts to 279.7m NOK.
What is Arctic Bioscience AS's Total Assets growth rate?
Total Assets CAGR 5Y
28%
Over the last year, the Total Assets growth was -7%. The average annual Total Assets growth rates for Arctic Bioscience AS have been -6% over the past three years , 28% over the past five years .
